University of Minnesota Medical School receives $945K to advance stem cell therapy

Eric Oliver -   Print  |

Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy.

The grant supports efforts around the preclinical discovery phase of analysis. Patients who suffer from Duchenne muscular dystrophy cannot develop a protein vital for strength-building, and gradually suffer from muscle deterioration. The stem cell treatment can be used to replace the diseased muscle tissue with healthy muscle. It also creates healthy myofibers that create proteins.

If the preclinical phase is successful, researchers will begin a phase 1 study.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers